Premium
Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats
Author(s) -
Tang Yu,
Liao Yonghui,
KawaguchiSakita Nobuko,
Raut Vikram,
Fakhrejahani Elham,
Qian Niansong,
Toi Masakazu
Publication year - 2011
Publication title -
journal of hepato‐biliary‐pancreatic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 1868-6974
DOI - 10.1007/s00534-010-0368-z
Subject(s) - pancreatitis , medicine , tumor necrosis factor alpha , nerve growth factor , pharmacology , acinar cell , endocrinology , gastroenterology , receptor
Background/purpose Sinisan, a traditional Chinese medicine, is effective for the treatment of gastrointestinal disorders. In this study, we investigated the potential protective role of Sinisan against chronic pancreatitis (CP) in rats. Methods CP was induced in rats by intrapancreatic injection of trinitrobenzene sulfonic acid (TNBS). Rats were randomly divided into a sham group, a TNBS‐induced CP group and a Sinisan‐treated group. Serum amylase and histological score were used to evaluate the severity of disease. The levels of tumor necrosis factor‐α (TNF‐α), interleukin‐1β (IL‐1β), cyclooxygenase‐2 (COX‐2), interleukin‐10 (IL‐10) and α‐smooth muscle actin (α‐SMA) were also measured in the three groups. Mechanical allodynia was measured with von Frey filaments. In addition, the protein levels of nerve growth factor (NGF) were measured in pancreatic tissues. Results Administration of Sinisan significantly decreased the severity of CP. In the Sinisan‐treated group, serum amylase, TNF‐α, IL‐1β, COX‐2 and α‐SMA levels were lower and the level of IL‐10 was upregulated compared with the TNBS‐induced CP group. Furthermore, treatment with Sinisan significantly, though not completely, attenuated the allodynia. Simultaneously NGF expression was also significantly downregulated in the Sinisan‐treated group compared with the TNBS‐induced CP group. Conclusions Sinisan could be an effective treatment modality for CP via its anti‐inflammatory, anti‐fibrotic and analgesic properties. It may be a promising drug candidate for the treatment of patients with CP.